The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
Agency Information Collection Activities: Proposed Collection; Comment Request (Negative Option Rule)
Agency Information Collection Activities: Submission for OMB Review; Comment Request (Franchise Rule)
1409005 Informal Interpretation
1409004 Informal Interpretation
Federal Trade Commission Comment Before the Federal Communications Commission Regarding the Privacy and Security Practices of Broadband Providers and Their Impact On Broadband Adoption
20141552: Berkshire Fund VIII, L.P.; Access Information Holdings, LLC
Akorn, Inc., In the Matter of
Akorn, Inc. has agreed to sell its rights to develop, manufacture, and market the generic injectable tuberculosis drug, rifampin, in order to settle FTC charges that Akorn’s proposed acquisition of VersaPharm Inc. and its parent company, VPI Holdings Corp., would likely be anticompetitive. According to the FTC’s complaint, only VersaPharm and two other firms currently have FDA approval to sell generic injectable rifampin and there are no viable substitutes for rifampin as a course of treatment for tuberculosis. The FTC’s proposed settlement with Akorn requires the company to divest its Abbreviated New Drug Application for generic injectable rifampin – which is currently pending before the Food and Drug Administration – to Watson Laboratories, Inc.